| Literature DB >> 35664865 |
Yi Liao1, Lingling Liu1, Hua Zhou1, Feng Fang1, Xinglou Liu1.
Abstract
Listeria innocua is widely distributed in the environment and food and is considered a non-pathogenic bacterium for both humans and animals. To our knowledge, only a few cases of L. innocua infection in humans and ruminants have been reported. Moreover, there has been no report on human L. innocua meningoencephalitis. Here, we report a case of severe refractory meningoencephalitis in a three-year-old boy after infection with L. innocua. The child's first symptoms were a runny nose, high fever, and rashes, which quickly progressed to unconsciousness and convulsions. The initial analysis of cerebral spinal fluid revealed remarkably elevated protein levels and increased white blood cells count. The blood culture of the patient in the early stage was positive for L. innocua. In addition, his brain imaging tests were observed dynamically, and the result showed a speedy progression from multiple intracranial abnormal signals to hydrocephalus and interstitial cerebral edema. After receiving antibiotics and symptomatic treatment for nearly 3 months, the patient's condition improved markedly. However, he still had residual complications such as hydrocephalus. Although L. innocua is considered harmless, it can still cause disease in humans, even severe meningoencephalitis, with rapid progression and poor prognosis. Early discovery, diagnosis, and treatment are necessary to elevate the survival rate and life quality of those patients. Antibiotics should be used with sufficient duration and dosage. Cephalosporins are not suitable for the treatment of L. innocua meningoencephalitis and penicillin antibiotics are preferred for children. The presentation of this case will help to expand our knowledge of Listeria infections and provide a potential candidate for pathogens causing severe childhood central nervous system infection.Entities:
Keywords: Listeria innocua; blood culture; hydrocephalus; infection; meningoencephalitis
Year: 2022 PMID: 35664865 PMCID: PMC9160653 DOI: 10.3389/fped.2022.857900
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.569
FIGURE 1A timeline with relevant data from the patient episode of care. WBC, white blood cell; CRP, C-reactive protein; LDH, lactate dehydrogenase; CK, creatine kinase; ALT, alanine aminotransferase; CSF, Cerebral spinal fluid.
Lumbar puncture and CSF analysis findings.
| Cerebrospinal fluid | Results | |||
| March 6 | March 30 | April 16 | ||
| Appearance | Yellowish and clear | Clear | Yellowish and clear | |
| Protein level (mg/L) | 3,057↑ | 747↑ | 829↑ | |
| Glucose (mmol/L) | 4.05 | 3.68 | 4.23 | |
| Chloride (mmol/L) | 120 | 117 | 118 | |
| Lactate dehydrogenase (U/L) | 973↑ | 58↑ | 27 | |
| Stains and smears | Negative | Negative | Gram stain (-), | |
| Bacterial culture | Negative | Negative | Negative | |
| White blood cell | Counts (× 106/L) | 145 | 7 | 2 |
| Neutrophils (%) | 26 | - | - | |
| Lymphocytes (%) | 74 | - | - | |
FIGURE 2Imaging tests of the patient. (A) Imaging tests of the brain. (a) Brain diffusion-weighted MRI on 6 March 2020 revealed multiple intracranial abnormal signals with the slightly enlarged posterior horn of the lateral ventricle (white arrow). (b) CT scan of the brain on 16 April 2020 showed hydrocephalus and interstitial edema of white matter. (c) T2-Flair MRI images of the brain on 22 April 2020 showed multiple patchy shadows in the splenium of the corpus callosum, frontal lobe, and left basal ganglia, suggesting infectious changes. Hydrocephalus and interstitial edema were also observed. (B) Imaging tests of the lung. (a) The initial lung X-ray image of the patient on 12 March 2020 showed infection in the bilateral lungs. (b) CT scan of the lung on 16 April 2020 revealed patchy shadows on bilateral lungs, suggesting infection.
Further laboratory examinations of the patient.
| Examinations | Test details | Results |
|
| ||
| - Epstein-Barr virus | Antibody test | VCA-IgG (+), EA-IgG (+), EBNA-IgG (+), VCA-IgM (-) |
| Nucleic acid | Whole blood (-), plasma (-) | |
| - The nine pathogens of respiratory tract infection (IgM antibodies) | Legionella pneumophila serogroup 1, Mycoplasma pneumoniae, | All negative |
| - Fungi | β- | Negative |
| Galactomannan assay | Negative | |
| - SARS-CoV-2 | Antibody test | IgG (-), IgM (-) |
| Nucleic acid | Negative | |
| - TORCH | Antibody test of IgM | All negative |
| - Hepatitis viruses | Antibody test for Hepatitis A, B, C, E | All negative |
| - Treponema pallidum | Antibody test | Negative |
| - Parvovirus B19 | Antibody test | Negative |
| - Tuberculosis | T-SPOT.TB test | Negative |
|
| ||
| - Assays of circulating cytokines | - | IL-1β↑, IL-2R↑, IL-6↑, IL-8↑, IL-10↑, TNF-α↑ |
| - Lymphocyte subset analysis | Cell count (cells/μl)/proportion (%) | Total T cells: 3,520/94.51↑ |
| - Immunoglobulin and Complement Test | IgA, IgG, IgM, C3 and C4 | IgA↓, IgM↓ |
| - Autoantibody test for autoimmune encephalitis, hepatitis, and systemic autoimmune diseases | Both blood and cerebrospinal fluid | All negative |
|
| -Lactic acid and pyruvate testing | In normal range |
| -Amino acids blood test | No obvious abnormalities | |
| -Urine organic acids analysis | No obvious abnormalities |
VCA, viral capsid antigen; EA, early antigen; EBNA, EBV nuclear antigen; TORCH, stands for toxoplasmosis, rubella, cytomegalovirus (CMV), and herpes simplex virus (HSV).